Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.
- Authors: D'Amico E., Zanghì A., Sciandra M., Borriello G., Callari G., Gallo A., Salemi G., Cottone S., Buccafusca M., Valentino P., Bossio RB., Grimaldi LME., Pozzilli C., Tedeschi G., Zappia M., Patti F.
- Publication year: 2018
- Type: Articolo in rivista (Articolo in rivista)
- Key words: Dimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide
- OA Link: http://hdl.handle.net/10447/334835
Abstract
A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days.